A Single $249 Test Analyzes 30 Cancer Genes. But Do You Need It?
By Sarah Zhang,
WIRED
| 04. 28. 2016
Untitled Document
The breast cancer genes BRCA1 and BRCA2 ar two of the famous sequences of DNA in the world. In the 90s, their discovery upended cancer research, kicking off a frenzy to find other genes linked to cancer. That in turn kicked off another frenzy: of companies selling kits that test for ever-more newly discovered cancer genes. Today, the cancer genetics startup Color Genomics is announcing that it will expand its test for breast and ovarian cancer genes to include a total of 30, including genes related to pancreatic, stomach, colon, and prostate cancer.
Color stands out among the field because of its price: $249. That’s cheap enough to leapfrog insurance companies, the traditional gatekeepers of genetic tests. Insurance typically only covers genetic tests for cancer—which can run to over a thousand dollars among Color’s competitors—if a patient has risk factors like family history of cancer at a young age. Color also helpfully refers would-be customers to doctors to order the test. “Historically the test has been very expensive, and the process to get testing meant jumping through lots...
Related Articles
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...